63 results about "Hydrobromide" patented technology

The invention belongs to the technical field of flame retardants, and particularly relates to a melamine hydrobromide flame retardant and a preparation method thereof. The flame retardant disclosed by the invention has a core-shell structure, the core is hydroxylated melamine hydrobromide subjected to surface modification by a silane coupling agent, and the shell is melamine resin synergistically enhanced by ammonium polyphosphate and oxidized cellulose nanofibrils; through silanization treatment, core-shell interface combination is enhanced, and space-time synergy of gas phase and condensed phase flame retardance is achieved through a composite shell; the obtained flame retardant is high in thermal stability in a polymer matrix, the limit oxygen index of a composite material can be remarkably increased after the flame retardant is added, and the flame retardant has a wide application prospect in the field of flame retardance of high polymer materials through a UL-94 V-0 grade test.

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

The application provides a preparation method of low-impurity vonerogefumate. The application provides a method for removing impurities A-E in the preparation of vonerogefumate, wherein vonerogefumate is reacted with hydrobromic acid to obtain vonerogefumate hydrobromide, and the method specifically comprises the following steps: (1) dissolving vonerogefumate and hydrobromic acid in a solvent; (2) cooling or directly precipitating a solid; and (3) separating to obtain vonerogefumate hydrobromide. The method can remove impurities A-E which are difficult to remove by a recrystallization refining method, and the method has good selectivity for impurities A-E. The application provides an impurity D, a preparation method thereof and application of the impurity D as an impurity control sample of vonerogefumate.

The invention provides a composition containing picocetinib hydrobromide and a preparation method thereof, the composition is a tablet, the active component picocetinib hydrobromide and a hydrophilic gel framework material (e.g., hydroxypropyl methylcellulose, polyoxyethylene resin or hydroxypropyl methyl cellulose acetate succinate) form a solid dispersion, and the solid dispersion is prepared into the composition containing the picocetinib hydrobromide and the hydrophilic gel framework material (e.g., hydroxypropyl methylcellulose, polyoxyethylene resin or hydroxypropyl methyl cellulose acetate succinate). The solubility of the medicine is improved, and stable release in vivo is realized; according to the present invention, with the addition of the pH value adjusting agent, the solubility of the picetinib hydrobromide can be maintained without limitation in the neutral pH region, the stability is good, and the stable release in the body is achieved so as to achieve the rheumatic arthritis treatment effect, improve the patient comfort and the treatment compliance, reduce the administration frequency and the medical cost, reduce the side effect, and provide the clinical application prospect. The whole preparation method is simple and suitable for industrial production.

The invention discloses an analysis method for determining halogenated alkane impurities in tigliptin hydrobromide, and relates to the technical field of quality analysis. In order to solve the problem of detection of halogenated alkane impurities in tigliptin hydrobromide, the invention provides a convenient, efficient and accurate detection method. The method comprises the following steps: preparing a test solution and an impurity reference solution, and detecting by adopting a gas chromatographic method; the method can be used for accurately determining the content of halogenated alkane in tigliptin hydrobromide, plays a guiding role in development of a synthesis process, and contributes to establishment of quality standards of tigliptin hydrobromide bulk drugs.

The invention provides an X-ray luminescent crystal material containing heavy atoms as well as a preparation method and application thereof, and belongs to the technical field of luminescent materials. The chemical formula of the X-ray luminescent crystal material is 2XL at-AMnBr4, 2XL represents dihalogen substituted p-phenylenediamine hydrobromide, halogen atoms are one or two of Cl, Br and I, and A represents crown ether. According to the invention, heavy atoms are introduced into the organic cation module of the organic-inorganic hybrid metal halide through the multistage supramolecular self-assembly effect for the first time, the luminescence property and stability of the X-ray luminescent material are improved, and the luminescent quantum yield reaches 60% or more. The X-ray luminescent material provided by the invention is used as a scintillator of a core component, can efficiently convert X-rays into visible light signals, and provides more accurate and rapid analysis and detection for multiple fields such as safety inspection, scientific research, medical diagnosis and the like.

The invention provides a crystal form of a compound HIF-117 salt as well as a preparation method and application of the crystal form, and the crystal form is any one or more of the following crystal forms: a hydrochloride crystal form A, a sulfate crystal form B, a 1, 2-ethanedisulfonate crystal form C1, 1, 2-ethanedisulfonate crystal form C2, 1, 2-ethanedisulfonate crystal form C3 and 1, 2-ethanedisulfonate crystal form C4. The crystal form 1, 2-ethanedisulfonate crystal form C2, p-toluenesulfonate crystal form D, mesylate crystal form E1, mesylate crystal form E2, hydrobromide crystal form F1, hydrobromide crystal form F2, sodium salt crystal form G, sylvite crystal form H1, sylvite crystal form H2, calcium salt crystal form I, magnesium salt crystal form J, choline salt crystal form K, lysine salt crystal form L, ammonium salt crystal form M, meglumine salt crystal form N, betaine salt crystal form O1, betaine salt crystal form O2 and diethylamine salt crystal form P1, the invention relates to a diethylamine salt crystal form P1, a diethylamine salt crystal form P2, a diethylamine salt crystal form P3, a diethylamine salt crystal form P4, a diethylamine salt crystal form P5, a tromethamine salt crystal form Q1, a tromethamine salt crystal form Q2 and a tromethamine salt crystal form Q3. The compound has good stability, and has important value for development and production of medicines and preparations.

The invention relates to a polymorphic form of hydrobromide or hydrochloride of 5-(6-(4-(cyclopropylmethyl) piperazine-1-yl)-2-methylpyridine-3-yl)-N-((4, 6-dimethyl-2-oxo-1, 2-dihydropyridine-3-yl) methyl)-3-(N-ethylcyclopropanecarboxamide)-2-methylbenzamide, a pharmaceutical composition of the polymorphic form and application of the polymorphic form and the pharmaceutical composition of the hydrobromide or hydrochloride of the 5-(6-(4-(cyclopropylmethyl) piperazine-1-yl)-2-methylpyridine-3-yl)-N-(4, 6-dimethyl-2-oxo-1, 2-dihydropyridine-3-yl)-3-(N-ethylcyclopropanecarboxamide.

This application discloses an analytical method for N-nitrosamine vortioxetine in vortioxetine hydrobromide tablets, belonging to the field of pharmaceutical impurity analysis. The method employs high-performance liquid chromatography (HPLC), with the following chromatographic conditions: a 4.6 mm × 250 mm column packed with octadecylsilane-bonded silica gel, with a particle size of 5 μm; mobile phase A is a 90:10 water-acetonitrile mixture containing 0.025%–0.035% trifluoroacetic acid (v / v); mobile phase B is acetonitrile; gradient elution; column temperature 38–42 °C; flow rate 0.9–1.1 ml / min; injection volume 50 μl; and detection wavelength 226 nm. This analytical method effectively eliminates excipient interference and exhibits excellent detection performance (specificity, sensitivity, linearity, precision, accuracy, and robustness), accurately detecting the content of N-nitrosamine vortioxetine in vortioxetine hydrobromide tablets, meeting quality control requirements.

The invention discloses a preparation method of hydrobromic acid vortioxetine, and belongs to the technical field of organic synthesis. The method comprises the following steps: by taking o-aminothiophenol and Boc2O as initial raw materials, carrying out amino protection to obtain an intermediate 1; reacting the intermediate 1 with 2, 4-dimethyl bromobenzene under an alkaline condition to form a thioether bond, and acidifying to obtain an intermediate 2; carrying out high-temperature cyclization on the intermediate 2 and bis (2-bromoethyl) amine hydrobromide in mesitylene, so as to obtain a crude product of the hydrobromic acid vortioxetine; and recrystallizing the crude product with 95% ethanol to obtain a high-purity final product. The route is simple, only three-step reaction is needed, a noble metal catalyst is not needed in the whole process, and the problem of metal residues is fundamentally avoided; the selected raw materials are easy to obtain, the reaction condition is mild, the operation is simple and convenient, the process is stable, the total yield is good, the product purity is as high as 99.9%, and the method is suitable for large-scale production.

The present invention relates to polymorphs of the hydrobromide salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazangrate), more specifically Form A, Form B, and Form C of the HBr salt of linaprazangrate. The present invention also relates to pharmaceutical compositions containing such polymorphs and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory or gastric acid-related diseases, particularly erosive gastroesophageal reflux disease (eGERD).

The invention relates to guanidine-containing hydrobromide electrolyte for a high-energy-density zinc-bromine-iodine battery as well as a preparation method and application of the guanidine-containing hydrobromide electrolyte, and belongs to the technical field of aqueous zinc-bromine-iodine batteries. The guanidine hydrobromide-containing electrolyte for the high-energy-density zinc-bromine-iodine battery comprises guanidine hydrobromide, zinc salt and deionized water. According to the guanidine-containing hydrobromide electrolyte for the high-energy-density zinc-bromine-iodine battery, provided by the invention, redox of iodine valence state I-I0I < + > and redox of bromine valence state BrBr0 can be realized at the same time, and six-electron transfer of halogen compounds in the zinc-bromine-iodine battery is realized. On one hand, the energy density of the battery is increased to 3-4 times of the initial value, and on the other hand, the zinc-bromine-iodine battery containing the zinc-bromine-iodine battery has the advantages of being easy to manufacture and easy to industrially popularize.

The present invention relates to a process for the industrial-scale production of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol hemifumarate, a salt consisting of two molecules of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol and one molecule of fumaric acid, and having the following formula: 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol hemifumarate is a useful intermediate in the synthesis of 5-[(1RS)-2-[(1RS)-2-(4-hydroxyphenyl)-1-methylethyl]-amino-1-hydroxyethyl]benzene-1,3-diol hydrobromide, which is used in the pharmaceutical field under the is known by the common name fenoterol hydrobromide.

Novel crystalline forms of Nirogacestat dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing γ-secretase inhibitor drugs and drugs for treating desmoid tumors.

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:

The application relates to a large-size rare earth doped phenethylamine lead bromide perovskite monocrystal preparation method and perovskite monocrystal, and solves the technical problems that the preparation of the existing large-size rare earth doped two-dimensional perovskite monocrystal needs higher nucleation supersaturation, the preparation period is long, and part of the rare earth bromide is extremely easy to absorb moisture, thereby reducing the crystal quality. The large-size rare earth doped phenethylamine lead bromide perovskite monocrystal preparation method and perovskite monocrystal comprise the following steps: 1) weighing; phenethylamine hydrobromide, lead bromide and rare earth metal bromide are weighed and placed in a glass bottle; 2) obtaining a precursor solution; 3) obtaining a millimeter-level size crystal; 4) screening a seed crystal; and 5) seed crystal growth. In step 4), the open container B is placed at a preset temperature until the seed crystal continues to grow into a rare earth doped phenethylamine lead bromide perovskite monocrystal with a predetermined size, and the size can reach a centimeter level, which has an important supporting role in promoting the performance research of the rare earth doped two-dimensional perovskite monocrystal.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

The present application relates to a salt of a triazine compound, a crystal form thereof, and a method for producing the same. Provided are: a salt and a crystal of a triazine compound, which have an inhibitory effect on aldosterone synthetase and are useful as a drug, particularly a prophylactic or therapeutic drug for primary aldosterone hyperplasia and the like; and a method for producing the salt and the crystal of the triazine compound. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamido) cyclohexyl] carbamoylmethyl] piperazin-1-yl]-5-(p-tolyl)-1, 2, 4-triazine (wherein the salt is a hydrobromide salt, a sulfate salt, a succinate salt, a p-toluenesulfonate salt, or the like), and a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamido) cyclohexyl] carbamoylmethyl] piperazin-1-yl]-5-(p-tolyl)-1, 2, 4-triazine.

The application discloses a kind of wet etching liquid and etching method for InP-based disc microcavity, the etching liquid is made of hydrobromic acid, hydrochloric acid, hydrogen peroxide and deionized water is mixed, the etching liquid is placed under light shielding condition after preparation 4~8 hours.The etching method is to use the etching liquid and carry out etching under light shielding condition.The etching liquid is placed under light shielding condition after preparation, and the purpose is to make the microcosmic mass transfer of solution system after mixing and initial reaction reach equilibrium, eliminate the fluctuation caused by temporary concentration gradient, ensure the initial kinetic state of each etching is consistent.The application breaks through the traditional technical prejudice that "wet etching does not need to strictly avoid light", and first clearly establishes "full light shielding" as the key process variable to realize and lock the ideal etching morphology of InP-based microcavity, and cooperates with specific ratio to form a complete, stable and predictable process system.The discovery provides a new control dimension and theoretical basis for wet etching process.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosilate, and the like.

The present application provides a salt of a triazine compound having an inhibitory action against aldosterone synthase, which is useful as a medicine, particularly a prophylactic or therapeutic agent for primary aldosteronism and the like, a crystal thereof, and a production method thereof. Specifically, the present application provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetylamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is a hydrobromide, a sulfate, a succinate, or a p-toluenesulfonate, or the like.

The invention discloses a quality analysis method for separating and measuring tigliptin hydrobromide isomers, which relates to the technical field of quality analysis, and comprises the steps of high performance liquid chromatography conditions, preparation of a system applicability solution, preparation of a reference substance solution, preparation of a test solution and measurement. According to the method, a silica gel surface is covalently bonded with a cellulose-tri (3, 5-dichlorophenyl carbamate) column, a mobile phase is n-hexane-absolute ethyl alcohol-acetonitrile-ethanolamine-trifluoroacetic acid (10: 85: 5: 0.25: 0.1), the column temperature is 20-30 DEG C, the detection wavelength is 254 nm, and the flow velocity is 0.4-0.65 ml per minute. The method can be used for completely separating the tigliptin hydrobromide and the isomer thereof, and can be used for detecting the isomer in the tigliptin hydrobromide. The problem that isomers cannot be effectively separated by the existing detection method for the related substances of the tigliptin hydrobromide is solved.

The invention relates to a benzofuranone compound salt form and / or crystal form with a structure shown in a formula I as well as a preparation method and application of the benzofuranone compound salt form and / or crystal form. The invention provides a pharmaceutically acceptable salt of a benzofuranone compound as shown in a formula I. The pharmaceutically acceptable salt is one of hydrochloride, sulfate, phosphate, hydrobromide, maleate, tartrate, fumarate, citrate, p-toluenesulfonate, benzene sulfonate, mesylate, succinate, acetate and lactate. The salt formed by the compound shown in the formula I has a structure shown in a formula II, and n is selected from 1 or 2. The dynamic solubility is better, the stability is better, the absorption of the medicine, the stability of the medicine effect and the storage stability are facilitated, and the pharmaceutical prospect is better.

The invention belongs to the technical field of flame retardants, and particularly relates to a melamine hydrobromide flame retardant and a preparation method thereof. Dopamine hydrochloride is attached to the surface of melamine hydrobromide through auto-polymerization, after heating, a polydopamine group bond is broken and recombined into a polydopamine derived carbon material, the polydopamine derived carbon material and a graphitized carbon layer generated by heating graphene oxide jointly form a compact layer, oxygen is isolated, and the flame retardant property of the melamine hydrobromide flame retardant is improved; graphene oxide-polyolefin elastomer-maleic anhydride and polydopamine are condensed to form an amido bond coating network, so that molecular-level dispersion of a graphene oxide-polyolefin elastomer-maleic anhydride coating layer on the surface of melamine hydrobromide is realized, and the compatibility of the melamine hydrobromide flame retardant and a polypropylene substrate is improved.

Providing a solid form of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalene-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazole-4-yl)pentanamide and its use. [Solution] This disclosure relates to a) a solid form of hydrobromide of compound 1; b) a pharmaceutical composition comprising one or more solid forms of hydrobromide of compound 1 and, optionally, a pharmaceutically acceptable carrier; c) a method for treating a tumor or cancer by administering one or more solid forms of hydrobromide of compound 1 to a subject requiring it; and d) a method for preparing a solid form of compound 1.

The invention relates to an industrial large-scale preparation method of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl) amino]-1-hydroxyethyl} benzene-1, 3-diol hemifumarate, the salt is composed of two molecules of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl) amino]-1-hydroxyethyl} benzene-1, 3-diol and one molecule of fumaric acid, and the two molecules of fumaric acid are different from each other. The compound has the following structural formulas (2) and (1). The 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl) amino]-1-hydroxyethyl} benzene-1, 3-diol hemifumarate is a useful intermediate for synthesizing 5-[(1RS)-2-[(1RS)-2-(4-hydroxyphenyl)-1-methylethyl) amino]-1-hydroxyethyl] benzene-1, 3-diol hydrobromide, and the common name of fenoterol hydrobromide in the pharmaceutical field is known by people.

The application relates to a benzofuranone compound salt type and / or crystal type with a structure of formula I and a preparation method and application thereof. The application provides a pharmaceutically acceptable salt of a benzofuranone compound shown in formula I, wherein the pharmaceutically acceptable salt is one of hydrochloride, sulfate, phosphate, hydrobromide, maleate, tartrate, fumarate, citrate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, succinate, acetate and lactate; the salt formed by the compound of formula I has a structure as shown in formula II, and n is selected from 1 or 2. The dynamic solubility is better, the stability is better, the drug absorption is facilitated, the drug efficacy is stable, the storage stability is good, and the application prospect is better.

The application belongs to the technical field of medicine synthesis process, and particularly relates to a preparation method of high-yield and high-purity buspirone hydrochloride. The application takes 8-(2-pyrimidyl)-8-azido-5-5-azospiro[4.5]decane hydrobromide (referred to as pyrimidine piperazine quaternary ammonium salt) and 3,3-tetramethylene glutarimide as raw materials, takes a mixed solvent of toluene, normal pentanol and / or normal hexanol as a solvent, does not need to add a phase transfer catalyst, and can generate buspirone in the presence of sodium carbonate. After acid adjustment and extraction, toluene is removed in the reverse phase, the water phase is adjusted to be alkaline, toluene is extracted, hydrogen chloride ethanol solution is added, and buspirone hydrochloride solid is directly precipitated. The preparation process has a good removal effect on impurities, the obtained buspirone hydrochloride has high purity, high process yield, good atomic economy and small three-waste output.

The application discloses a kind of ambient temperature fast-curing cardanol curing agent and its preparation method and application;The application is prepared by 2-bromoethylamine hydrobromide, potassium hydroxide and anhydrous ethanol after mixing reaction 2-bromoethylamine;Cardanol, diethylene triamine DETA, formaldehyde solution are mixed after reaction to obtain cardanol curing agent intermediate PK3;2-bromoethylamine, PK3, potassium carbonate and acetone are mixed after reaction to prepare ambient temperature fast-curing cardanol curing agent PK3-ENH2.The ambient temperature fast-curing cardanol curing agent production process of the application is simple, and the production equipment is not high in requirement.The ambient temperature fast-curing cardanol curing agent of the application has good chemical resistance, adhesion, physical and mechanical properties of solvent type epoxy coating, and has the characteristics of low pollution, simple construction, etc.